inclusion criteria: * capable of understanding and providing signed informed consent and ability to adhere to the requirements and restrictions of this protocol; * men and women ≥ 18years of age; * internet access and capability and willingness to use to participate in audio or audio/video engagements with medical professionals, receive texts, emails, and phone calls from study staff and have a device and reasonable cellular data or other internet access to submit daily study required information using a smart phone, tablet, laptop, or desktop computer during the study period; * covid-19 infection confirmed with a laboratory antigen or sars-cov-2 rt-pcr nasal swab; * specimen collected within the past 48 hours; * mild covid /flu symptoms which may include no symptoms, fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, lack of taste or smell without shortness of breath or dyspnea; * must be willing to use one highly effective birth control method which include: abstinence, hormonal contraceptives (e.g. combined oral contraceptives, patch, vaginal ring, injectables, and implants); intrauterine device (iud) or intrauterine system (ius); vasectomy and tubal ligation or to use two forms of effective birth control methods which include: barrier methods of contraception (e.g. male condom, female condom, cervical cap, diaphragm, contraceptive sponge); * hormonal methods and the iud must be in use at least 30 days prior to first study drug administration * abstinence and barrier methods must be in use at least 14 days prior to study drug administration * vasectomy must be completed 3 months prior to first study drug administration; or in the alternative that a 0 sperm count will suffice.

inclusion criteria: * capable of understanding and providing signed informed consent and ability to adhere to the requirements and restrictions of this protocol; * men and women ≥ 18years of age; * internet access and capability and willingness to use to participate in audio or audio/video engagements with medical professionals, receive texts, emails, and phone calls from study staff and have a device and reasonable cellular data or other internet access to submit daily study required information using a smart phone, tablet, laptop, or desktop computer during the study period; * covid-19 infection confirmed with a laboratory antigen or sars-cov-2 rt-pcr nasal swab; * specimen collected within the past 48 hours; * mild covid /flu symptoms which may include no symptoms, fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, lack of taste or smell without shortness of breath or dyspnea; * must be willing to use one highly effective birth control method which include: abstinence, hormonal contraceptives (e.g. combined oral contraceptives, patch, vaginal ring, injectables, and implants); intrauterine device (iud) or intrauterine system (ius); vasectomy and tubal ligation or to use two forms of effective birth control methods which include: barrier methods of contraception (e.g. male condom, female condom, cervical cap, diaphragm, contraceptive sponge); * hormonal methods and the iud must be in use at least 30 days prior to first study drug administration * abstinence and barrier methods must be in use at least 14 days prior to study drug administration * vasectomy must be completed 3 months prior to first study drug administration; or in the alternative that a 0 sperm count will suffice.

inclusion criteria: - capable of understanding and providing signed informed consent and ability to adhere to the requirements and restrictions of this protocol; - men and women ≥ 18years of age; - internet access and capability and willingness to use to participate in audio or audio/video engagements with medical professionals, receive texts, emails, and phone calls from study staff and have a device and reasonable cellular data or other internet access to submit daily study required information using a smart phone, tablet, laptop, or desktop computer during the study period; - covid-19 infection confirmed with a laboratory antigen or sars-cov-2 rt-pcr nasal swab; - specimen collected within the past 48 hours; - mild covid /flu symptoms which may include no symptoms, fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, lack of taste or smell without shortness of breath or dyspnea; - must be willing to use one highly effective birth control method which include: abstinence, hormonal contraceptives (e.g. combined oral contraceptives, patch, vaginal ring, injectables, and implants); intrauterine device (iud) or intrauterine system (ius); vasectomy and tubal ligation or to use two forms of effective birth control methods which include: barrier methods of contraception (e.g. male condom, female condom, cervical cap, diaphragm, contraceptive sponge); - hormonal methods and the iud must be in use at least 30 days prior to first study drug administration - abstinence and barrier methods must be in use at least 14 days prior to study drug administration - vasectomy must be completed 3 months prior to first study drug administration; or in the alternative that a 0 sperm count will suffice.

inclusion criteria: - capable of understanding and providing signed informed consent and ability to adhere to the requirements and restrictions of this protocol; - men and women ≥ 18years of age; - internet access and capability and willingness to use to participate in audio or audio/video engagements with medical professionals, receive texts, emails, and phone calls from study staff and have a device and reasonable cellular data or other internet access to submit daily study required information using a smart phone, tablet, laptop, or desktop computer during the study period; - covid-19 infection confirmed with a laboratory antigen or sars-cov-2 rt-pcr nasal swab; - specimen collected within the past 48 hours; - mild covid /flu symptoms which may include no symptoms, fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, lack of taste or smell without shortness of breath or dyspnea; - must be willing to use one highly effective birth control method which include: abstinence, hormonal contraceptives (e.g. combined oral contraceptives, patch, vaginal ring, injectables, and implants); intrauterine device (iud) or intrauterine system (ius); vasectomy and tubal ligation or to use two forms of effective birth control methods which include: barrier methods of contraception (e.g. male condom, female condom, cervical cap, diaphragm, contraceptive sponge); - hormonal methods and the iud must be in use at least 30 days prior to first study drug administration - abstinence and barrier methods must be in use at least 14 days prior to study drug administration - vasectomy must be completed 3 months prior to first study drug administration; or in the alternative that a 0 sperm count will suffice.